SCHEMBL334513

SCHEMBL334513

CC(C)(C)[Si](C)(C)Oc1ccccc1CC1CO1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
GLA P06280 1/20 0.41
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
RIPK1 Q13546 2/20 0.34
TDP1 Q9NUW8 1/20 0.33
DRD4 P21917 1/20 0.33
CYP2D6 P10635 1/20 0.33
TP53 P04637 2/20 0.33
MAPT P10636 2/20 0.33
HPGD P15428 2/20 0.33
TSHR P16473 2/20 0.33
CYP1A2 P05177 1/20 0.33
CTSB P07858 1/20 0.33
PPARG P37231 1/20 0.33
HIF1A Q16665 1/20 0.33
PREP P48147 1/20 0.31
SLC6A2 P23975 1/20 0.30
HTR1A P08908 1/20 0.30
ADRA2A P08913 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336148 0.79 IDO1 (0.39) ALDH1A1MEN1KMT2ATP53MAPT
Bromide SCHEMBL4071853 0.78 RIPK1 (0.34) ALDH1A1MEN1KMT2ARIPK1MAPT
SCHEMBL7240943 0.77 RIPK1 (0.36) RIPK1PREP
SCHEMBL15283292 0.77 RIPK1 (0.36) RIPK1PREP
SCHEMBL2325955 0.77 RIPK1 (0.36) RIPK1PREP
SCHEMBL9853837 0.77 L3MBTL1 (0.44) KMT2ARIPK1MAPTHPGDPREP
SCHEMBL7114249 0.77 CYP2D6 (0.50) ALDH1A1GLACYP2D6MAPTHPGD
SCHEMBL6305830 0.77 ALDH1A1 (0.46) ALDH1A1GLAMEN1KMT2ARIPK1
SCHEMBL1312619 0.77 ALDH1A1 (0.46) ALDH1A1GLAMEN1KMT2ARIPK1
SCHEMBL3372443 0.77 ALDH1A1 (0.46) ALDH1A1GLAMEN1KMT2ARIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 ALDH1A1 1939/4885GLA 141/4885MEN1 2456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.